J. Joseph Melenhorst, PhD
Results from a recent study may show why some patients with chronic lymphocytic leukemia (CLL) are resistant to tisagenlecleucel (Kymriah), while potentially offering a pathway to enhance patient response.
The study, led by senior author J. Joseph Melenhorst, PhD, and first author Joseph A. Fraietta, PhD, both faculty at the University of Pennsylvania, Department of Pathology and Laboratory Medicine, at the Center for Cellular Immunotherapies, demonstrated that patients with healthier, “early memory” cytotoxic T cells were far more likely to have a complete or partial response to treatment. In a validation study, this early memory T cell signature predicted patients who would experience CR with 100% accuracy.
... to read the full story